Postinflammatory hyperpigmentation: A comprehensive overview : Treatment options and prevention - 14/09/17
Abstract |
Postinflammatory hyperpigmentation (PIH) occurs after various dermatoses, exogenous stimuli, and dermatologic procedures. The clinical course of PIH is chronic and unpredictable, although the probability of resolution of epidermal hyperpigmentation is better than those of dermal hyperpigmentation. PIH can be prevented or alleviated. When it does occur, the underlying inflammatory conditions should be sought and treated as the first step to reduce the progression of inflammation and PIH (which is an inflammatory consequence). If the inflammatory conditions subsides or there is no evidence of inflammation at the time of diagnosis, the treatments of PIH should be considered as the next step. Understanding the available treatment options helps the physician choose the appropriate treatment for each patient. Having a reproducible model for PIH is essential for the development of treatment modalities. The second article in this 2-part continuing medical education series on PIH specifically addresses the evidence that supports medical and procedural treatments of PIH and other forms of acquired hyperpigmentation. It also describes a PIH model and provides an algorithm for clinical practice along with discussion about the prevention of PIH.
Le texte complet de cet article est disponible en PDF.Key words : bleaching agent, botanical, chemical peeling, hydroquinone, hyperpigmentation, laser and light, melanin, photoprotection, sunscreen, trichloroacetic acid
Abbreviations used : DOPA, GA, l-DOPA, NAG, PIH, QS, RCT, TA, TCA, UV
Plan
Drs Chaowattanapanit and Silpa-archa contributed equally to this article. |
|
Funding sources: None. |
|
Dr Kohli is a subinvestigator for Ferndale Laboratories, Estee Lauder, Johnson & Johnson, and Allergan, and is a consultant for Pfizer. Dr Hamzavi is an investigator for Clinuvel, Estee Lauder, Allergan, Ferndale Laboratories, and Johnson & Johnson, and is a consultant for Aclaris Therapeutics. Dr Lim has served as a consultant for Pierre Fabre and is an investigator for Clinuvel, Estee Lauder, and Ferndale Laboratories. Drs Silpa-archa and Chaowattanapanit have no conflicts of interest to declare. |
|
Date of release: October 2017 |
|
Expiration date: October 2020 |
Vol 77 - N° 4
P. 607-621 - octobre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?